Disease · MONDO_0005804

hyperprolactinemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperprolactinemia. Diseases, record MONDO_0005804. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005804

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperprolactinemia; Open Targets
Open Targets ID: MONDO_0005804; Open Targets
Other names: Chiari-Frommel Syndrome, Increased circulating prolactin concentration, Pregnancy-related A-G syndrome (disorder), Prolactin excess, hyperprolactinaemia, hyperprolactinemia (disease); Open Targets
MeSH: D006966; MeSH
Highest stage of its drugs: Approval, for 6 of its 14 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CABERGOLINE	CHEMBL1201087	Small molecule	Approval	TTD	5	4	4	Drugs and targets
BROMOCRIPTINE MESYLATE	CHEMBL1200503	Small molecule	Approval	DailyMed and FDA	4	1	1	Drugs and targets
ERENUMAB	CHEMBL3833329	Antibody	Approval	TTD	1	0	0	Drugs and targets
FREMANEZUMAB	CHEMBL4297756	Antibody	Approval	TTD	1	0	0	Drugs and targets
GALCANEZUMAB	CHEMBL3707328	Antibody	Approval	TTD	1	0	0	Drugs and targets
QUINAGOLIDE	CHEMBL2218861	Small molecule	Approval	TTD	1	0	0	Drugs and targets
BROMOCRIPTINE	CHEMBL493	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CALCIUM	CHEMBL1200496	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOMIPHENE CITRATE	CHEMBL3185958	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets61

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	6	D2-like dopamine receptor agonist; Dopamine D2 receptor agonist; Dopamine D2 receptor partial agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	3	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	3	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
CALCA	Calcitonin gene-related peptide	2	Calcitonin gene-related peptide antagonist; Calcitonin gene-related peptide inhibitor	Approval	https://conductscience.org/library/genes/796	Drugs and targets
CALCB	Calcitonin gene-related peptide	2	Calcitonin gene-related peptide antagonist; Calcitonin gene-related peptide inhibitor	Approval	https://conductscience.org/library/genes/797	Drugs and targets
CALCRL	Calcitonin gene-related peptide type 1 receptor	1	Calcitonin gene-related peptide type 1 receptor antagonist	Approval	https://conductscience.org/library/genes/10203	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/56901	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor alpha modulator	Phase 2	https://conductscience.org/library/genes/2099	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Unknown	https://conductscience.org/library/genes/2820	Drugs and targets

1 to 10 of 61

See all 61 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01270711	Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)		22,014	2014-03-24	Parkinson's Disease, Hyperprolactinemia	CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT01338298	Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia	Not applicable	60	2018-05-16	Hyperprolactinemia	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00799383	Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia	Phase 3	47	2017-12-26	Risperidone-induced Hyperprolactinemia	CALCIUM, ERGOCALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT02956447	Administration of Kisspeptin in Patients With Hyperprolactinemia	Phase 2	36	2024-08-20	Hyperprolactinemia, Hypogonadism	KISSPEPTIN	Its record names the disease	ClinicalTrials.gov
NCT03038308	Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole	Phase 1/2	16	2021-07-30	Hyperprolactinemia, Prolactinoma	ROPINIROLE	Its record names the disease	ClinicalTrials.gov
NCT03709849	Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility	Phase 2	528		Anovulatory Infertility, Abnormal Uterine Bleeding-Ovulatory Disorders, Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteinized Unruptured Follicle Syndrome, Corpus Luteum Insufficiency, Ovarian Insufficiency	CLOMIPHENE CITRATE	Its record names the disease	ClinicalTrials.gov
NCT07124221	A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets	Phase 3	382		Hyperprolactinemia	BROMOCRIPTINE MESYLATE, CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT02013232	Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia	Not applicable	120		Schizophrenia	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04262024	Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.	Phase 1	120		Health Education	CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT01957839	Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients	Phase 4	48		Adverse Reaction to Other Drugs and Medicines	CABERGOLINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Calcium+VitD vs Placebo: deaths from any cause	0 of 23	0 of 24	47	NCT00799383	Trial comparisons
Calcium+VitD vs Placebo: serious adverse events	0 of 23	0 of 24	47	NCT00799383	Trial comparisons
Aripiprazole vs Placebo: deaths from any cause	0 of 20	0 of 18	38	NCT01338298	Trial comparisons
Aripiprazole vs Placebo: serious adverse events	0 of 20	0 of 18	38	NCT01338298	Trial comparisons
Intravenous Kisspeptin vs Subcutaneous Kisspeptin: deaths from any cause	0 of 21	0 of 15	36	NCT02956447	Trial comparisons
Intravenous Kisspeptin vs Subcutaneous Kisspeptin: serious adverse events	0 of 21	0 of 15	36	NCT02956447	Trial comparisons
Aripiprazole vs Placebo: To Test Whether Adjunctive Aripiprazole Will Improve Quality/Perceived Quality of Life.	7 of 14	1 of 11	25	NCT01338298	Trial comparisons
Aripiprazole vs Placebo: To Determine if Adjunct Aripiprazole Will Resolve or Improve Prolactin Related Hormonal Side Effects (Amenorrhea, Oligomenorrhea, Galactorrhea).	11 of 13	7 of 11	24	NCT01338298	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37715962	DERIVED	1	PubMed
35804385	DERIVED	1	PubMed
29112461	DERIVED	1	PubMed
25222841	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005804

GET https://conductscience.org/api/diseases/v1/MONDO_0005804/targets?page=2

API reference For AI assistants